-- 2026年5月4日，高级副总裁兼首席会计官兰道夫·A·瓦克(Randolph A. Wacker)出售了Nvent Electric (NVT)的4,094股股票，套现677,841美元。根据向美国证券交易委员会(SEC)提交的4号表格文件，瓦克目前控制着该公司共计49,873股普通股，其中49,873股为直接持有。 SEC文件链接： https://www.sec.gov/Archives/edgar/data/1720635/000089706926001024/xslF345X05/form4.xml
Related Articles
Asia
SSY Group's Protein Test Kits Get Device Registration Certificates from Hebei Regulator
SSY Group's (HKG:2005) full-range C-reactive and Serum Amyloid A/C-reactive protein test kits obtained medical device registration certificates from the Hebei Provincial Drug Administration of China, according to a Wednesday Hong Kong bourse filing.The kits are used for in vitro quantitative detection of C-reactive protein and serum amyloid A levels in human serum, plasma, or whole blood samples.
$HKG:2005
Asia
Nomura Adjusts Coforge's Price Target to INR2,100 From INR2,000, Keeps at Buy
Coforge (NSE:COFORGE, BOM:532541) has an average rating of overweight and mean price target of 1,658.15 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$BOM:532541$NSE:COFORGE
Research
Research Alert: Smith & Nephew Q1: Strong Sports Medicine Offsets Knee Implants Weakness
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Smith & Nephew (SN) posted Q1 2026 revenue of USD1,501M, in line with consensus, representing underlying growth of 3.1% (or 4.4% on an adjusted daily sales basis) but decelerating sequentially across all segments. Orthopaedics slowed to +0.8% (vs. Q4's +7.9%) due to U.S. Knee Implants weakness, while Sports Medicine & ENT remained solid at +6.7%. SN announced a new USD500M share buyback to be completed within the next 12 months and reaffirmed 2026 guidance of 6% underlying revenue growth and USD1.3B trading profit. The 2026 guidance for reported revenue guidance of 7.7% is above the current S&P Capital IQ consensus estimate of around 6.6%. We expect upcoming launches and continued execution of the new RISE strategy to underpin growth momentum. That said, execution on U.S. Knee Implants remains critical to monitor. In our view, the planned Q3 2026 launch of the cementless version of the LANDMARK Knee System represents an important catalyst to address persistent challenges in the Knee business.
$SNN